LOGIN  |  REGISTER
Recursion

Opthea to Participate in the 23ʳᵈ Annual Needham Virtual Healthcare Conference 

April 04, 2024 | Last Trade: US$3.34 0.11 3.41

MELBOURNE, Australia and PRINCETON, N.J., April 04, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that management will present at the 23rd Annual Needham Virtual Healthcare Conference and participate in one-on-one investor meetings on April 11, 2024.

23rd Annual Needham Virtual Healthcare Conference Presentation Details:

Date:Thursday, April 11th
Time:3:45 p.m. ET
Presenter:Frederic Guerard, Pharm D, CEO
Webcast LinkHere

A webcast of the Needham presentation can be accessed under “Events & Presentations” in the Investor Relations section of the Company’s website, www.opthea.com.

About Opthea

Opthea (ASX/NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to address the unmet need in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).

Opthea’s lead product candidate, sozinibercept, is being evaluated in two pivotal Phase 3 clinical trials (COAST, NCT04757636, and ShORe, NCT04757610,) for use in combination with standard-of-care anti-VEGF-A monotherapies to improve overall efficacy and deliver superior vision gains compared to the standard-of-care anti-VEGF-A agents. To learn more, visit our website and follow us on X and LinkedIn.

Authorized for release to ASX by Fred Guerard, CEO

Investor Enquiries

PJ Kelleher
LifeSci Advisors, LLC
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
Phone: 617-430-7579

Media:

Silvana Guerci-Lena
NorthStream Global Partners
This email address is being protected from spambots. You need JavaScript enabled to view it.

Join our email database to receive program updates:
Tel: +61 (0) 3 9826 0399, Email: This email address is being protected from spambots. You need JavaScript enabled to view it., Web: www.opthea.com

C4 Therapeutics

Stock Quote

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB